Consequently, the systematic review follows two trends of research—the role of the HER2 pathway in pancreatic carcinogenesis and the rate of HER2 positivity according to the following tumor subtypes: pancreatic adenocarcinoma, distal cholangiocarcinoma, and ampullary carcinoma. Here, ERBB2 is linked to pancreatic adenocarcinoma.